169 related articles for article (PubMed ID: 25385636)
1. Oncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K).
Ito Y; Hart JR; Ueno L; Vogt PK
Proc Natl Acad Sci U S A; 2014 Nov; 111(47):16826-9. PubMed ID: 25385636
[TBL] [Abstract][Full Text] [Related]
2. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
Hofmann BT; Jücker M
Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814
[TBL] [Abstract][Full Text] [Related]
3. Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β.
Ito Y; Vogt PK; Hart JR
Oncotarget; 2017 Aug; 8(34):55863-55876. PubMed ID: 28915558
[TBL] [Abstract][Full Text] [Related]
4. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
[TBL] [Abstract][Full Text] [Related]
5. Profiling of phosphatidylinositol 3-kinase (PI3K) proteins in insulin signaling pathway.
Chakraborty C; Doss CG; Bhatia R; Agoramoorthy G
Appl Biochem Biotechnol; 2015 Apr; 175(7):3431-46. PubMed ID: 25637510
[TBL] [Abstract][Full Text] [Related]
6. Binding of influenza A virus NS1 protein to the inter-SH2 domain of p85 suggests a novel mechanism for phosphoinositide 3-kinase activation.
Hale BG; Batty IH; Downes CP; Randall RE
J Biol Chem; 2008 Jan; 283(3):1372-1380. PubMed ID: 18029356
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of influenza A virus NS1 protein interaction with the p85beta, but not the p85alpha, subunit of phosphatidylinositol 3-kinase (PI3K) and up-regulation of PI3K activity.
Li Y; Anderson DH; Liu Q; Zhou Y
J Biol Chem; 2008 Aug; 283(34):23397-409. PubMed ID: 18534979
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic signaling of class I PI3K isoforms.
Denley A; Kang S; Karst U; Vogt PK
Oncogene; 2008 Apr; 27(18):2561-74. PubMed ID: 17998941
[TBL] [Abstract][Full Text] [Related]
9. Specific increase in p85alpha expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells.
Giorgino F; Pedrini MT; Matera L; Smith RJ
J Biol Chem; 1997 Mar; 272(11):7455-63. PubMed ID: 9054447
[TBL] [Abstract][Full Text] [Related]
10. Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase.
Ueki K; Yballe CM; Brachmann SM; Vicent D; Watt JM; Kahn CR; Cantley LC
Proc Natl Acad Sci U S A; 2002 Jan; 99(1):419-24. PubMed ID: 11752399
[TBL] [Abstract][Full Text] [Related]
11. Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement.
Brachmann SM; Yballe CM; Innocenti M; Deane JA; Fruman DA; Thomas SM; Cantley LC
Mol Cell Biol; 2005 Apr; 25(7):2593-606. PubMed ID: 15767666
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of GFP-Fusion p110α and p110β Isoforms of PI3K Signaling Pathway in Normal and Cancer Cells.
Singh P; Dar MS; Singh G; Jamwal G; Sharma PR; Ahmad M; Dar MJ
J Cell Biochem; 2016 Dec; 117(12):2864-2874. PubMed ID: 27167447
[TBL] [Abstract][Full Text] [Related]
13. SUMOylation modulates the stability and function of PI3K-p110β.
El Motiam A; de la Cruz-Herrera CF; Vidal S; Seoane R; Baz-Martínez M; Bouzaher YH; Lecona E; Esteban M; Rodríguez MS; Vidal A; Collado M; Rivas C
Cell Mol Life Sci; 2021 Apr; 78(8):4053-4065. PubMed ID: 33834259
[TBL] [Abstract][Full Text] [Related]
14. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.
Thorpe LM; Spangle JM; Ohlson CE; Cheng H; Roberts TM; Cantley LC; Zhao JJ
Proc Natl Acad Sci U S A; 2017 Jul; 114(27):7095-7100. PubMed ID: 28630349
[TBL] [Abstract][Full Text] [Related]
15. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
Li T; Wang J; Wang X; Yang N; Chen SM; Tong LJ; Yang CH; Meng LH; Ding J
J Pharmacol Exp Ther; 2010 Sep; 334(3):830-8. PubMed ID: 20522531
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
Echeverria I; Liu Y; Gabelli SB; Amzel LM
FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
[TBL] [Abstract][Full Text] [Related]
17. Involvement of PI3K in PKCepsilon-mediated oncogenic signal in rat colonic epithelial cells.
Marras E; Concari P; Cortellezzi L; Dondi D; De Eguileor M; Perletti G
Int J Oncol; 2001 Aug; 19(2):395-9. PubMed ID: 11445858
[TBL] [Abstract][Full Text] [Related]
18. Posttranscriptional regulation of the p85α adapter subunit of phosphatidylinositol 3-kinase in human leukemia cells.
Hofmann BT; Hoxha E; Mohr E; Schulz K; Jücker M
Leuk Lymphoma; 2011 Mar; 52(3):467-77. PubMed ID: 21077741
[TBL] [Abstract][Full Text] [Related]
19. Non-catalytic role of phosphoinositide 3-kinase in mesenchymal cell migration through non-canonical induction of p85β/AP2-mediated endocytosis.
Matsubayashi HT; Mountain J; Takahashi N; Deb Roy A; Yao T; Peterson AF; Saez Gonzalez C; Kawamata I; Inoue T
Nat Commun; 2024 Mar; 15(1):2612. PubMed ID: 38521786
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and biological characterization of tumor-associated mutations of p110alpha.
Denley A; Gymnopoulos M; Hart JR; Jiang H; Zhao L; Vogt PK
Methods Enzymol; 2008; 438():291-305. PubMed ID: 18413256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
